Ipsen

All categories, Deals and Financing

Ipsen to Acquire Memo Therapeutics for Up to EUR700M

Ipsen will acquire Memo Therapeutics for up to EUR700M including EUR200M upfront, adding potravitug, a Phase 2 monoclonal antibody for BK polyomavirus-associated nephropathy in kidney transplant recipients.

admin
July 1, 2026

All categories, Deals and Financing

Ipsen Acquires Kartos Therapeutics for Up to $1.75B

Ipsen agreed to acquire Kartos Therapeutics for $450 million upfront plus up to $1.3 billion in regulatory and commercial milestones, creating a total potential transaction value of $1.75 billion. The acquisition gives Ipsen control…

admin
June 29, 2026

Ipsen to Acquire Memo Therapeutics for Up to EUR700M

Ipsen Acquires Kartos Therapeutics for Up to $1.75B

Saturday Rounds